NCT00115791

Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter

A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Tolerance and Efficacy Study of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 276 (actual)
• Sponsor: Astellas Pharma Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to demonstrate the effectiveness of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm.

Conditions

• Atrial Flutter
• Atrial Fibrillation

Interventions

Type	Name	Description
DRUG	RSD1235	IV
DRUG	placebo	IV

Timeline

• Start date: 2004-06-01
• Primary completion: 2005-06-01
• Completion: 2005-06-01
• First posted: 2005-06-27
• Last updated: 2008-04-01

Locations

54 sites across 7 countries: United States, Argentina, Canada, Chile, Denmark, Mexico, Sweden